
Principle Research Associate
Publications
Fragment‐Merging Strategies with Known Pyrimidine Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis
– ChemMedChem
(2023)
18,
e202300240
(doi: 10.1002/cmdc.202300240)
Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference**
– Angewandte Chemie
(2023)
135,
(doi: 10.1002/ange.202300221)
Structure Based Discovery of Inhibitors of CYP125 and CYP142 from Mycobacterium tuberculosis
– Chemistry
(2023)
29,
e202203868
(doi: 10.1002/chem.202203868)
Pantothenate biosynthesis in Toxoplasma gondii tachyzoites is not a drug target.
– Int J Parasitol Drugs Drug Resist
(2023)
22,
1
(doi: 10.1016/j.ijpddr.2023.03.003)
Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference**
– Angew Chem Int Ed Engl
(2023)
62,
e202300221
(doi: 10.1002/anie.202300221)
Microfluidic preparation of composite hydrogel microparticles for the staining of microalgal cells.
– Colloids Surf B Biointerfaces
(2022)
221,
113026
Development of potent inhibitors by fragment‐linking strategies
– Chem Biol Drug Des
(2022)
100,
469
(doi: 10.1111/cbdd.14120)
Structural Characterization of Mycobacterium abscessus Phosphopantetheine Adenylyl Transferase Ligand Interactions: Implications for Fragment-Based Drug Design
– Front Mol Biosci
(2022)
9,
880432
(doi: 10.3389/fmolb.2022.880432)
Potential therapeutic targets from Mycobacterium abscessus (Mab): recently reported efforts towards the discovery of novel antibacterial agents to treat Mab infections
– RSC Med Chem
(2022)
13,
392
(doi: 10.1039/d1md00359c)
Discovery of Novel Inhibitors of Uridine Diphosphate-N-Acetylenolpyruvylglucosamine Reductase (MurB) from Pseudomonas aeruginosa, an Opportunistic Infectious Agent Causing Death in Cystic Fibrosis Patients.
– Journal of Medicinal Chemistry
(2022)
65,
2149
(doi: 10.1021/acs.jmedchem.1c01684)
- 1 of 9